Inflammation in Pulmonary Arterial Hypertension

Area of Science:

• Cardiopulmonary Medicine
• Immunology
• Vascular Biology

Background:

• Pulmonary artery hypertension (PAH) is a severe cardiopulmonary disease marked by pulmonary arteriole remodeling, leading to heart failure.
• The precise pathophysiology and cellular interactions driving PAH development and progression remain largely unknown.
• Current treatments focus on vasodilation but do not reverse vascular remodeling.

Purpose of the Study:

• To comprehensively review the role of inflammation in pulmonary hypertension (PH) development.
• To highlight key studies in human and animal models of PAH.
• To discuss current and potential future therapeutic strategies for PAH.

Main Methods:

• Review of existing literature on the inflammatory processes in PH.
• Focus on adaptive and innate immune cells, endothelium, pulmonary lymphatics, and genetic factors.
• Analysis of human and animal models to understand disease pathophysiology.

Main Results:

• Significant evidence suggests altered immune and vascular cells contribute to PAH progression.
• Inflammation, characterized by a pro-inflammatory environment and immune cell infiltration, is hypothesized to be vital.
• Current therapeutic approaches are insufficient for reversing vascular remodeling.

Conclusions:

• Inflammation plays a critical role in the development and progression of pulmonary hypertension.
• Further research into the inflammatory cascade is needed to identify effective therapeutic targets.
• Future treatments may focus on reversing or preventing vascular remodeling by targeting inflammatory pathways.